#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myeloproliferative neoplasm Alveolar rhabdomyosarcoma Glomerulonephritis membranous Haemophilia A without inhibitors Round cell liposarcoma Alexander disease Autologous haematopoietic stem cell transplant Keratosis follicular Uterine leiomyosarcoma Hypomagnesaemia Biotinidase deficiency Breast angiosarcoma Basal cell naevus syndrome Vulval cancer recurrent Heritable pulmonary arterial hypertension More trials…

    Learn about Rare Diseases

    Small intestine leiomyosarcoma – Trials in Disease Turner’s syndrome – Trials in Disease SAPHO syndrome – Basic Information Von Willebrand’s disease – Treatment Congenital hypotransferrinaemia Leiomyosarcoma metastatic – Treatment Hereditary ataxia – Treatment Lennox-Gastaut syndrome – Treatment Stevens-Johnson syndrome – Trials in Disease Mucous membrane pemphigoid More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sucrose Bt8009 Leuprorelin Acetate Pabinafusp Alfa Bay 3283142 Pevonedistat Tegafur RUBIDIUM CHLORIDE Fasudil Hydrochloride Air, Medicinal Jk06 OSIMERTINIB MESYLATE Pervi-Fus Imgn151 Isatuximab Orismilast H2-Receptor Antagonists Inotuzumab Ozogamicin Alpelisib Daunorubicin Hydrochloride More therapies…

    Learn about Your Condition

    Raynaud's phenomenon Lichen sclerosus Infectious pleural effusion Marfan's syndrome Tendon rupture Hepatitis D Tympanic membrane hyperaemia Breast angiosarcoma Antisynthetase syndrome Venous thrombosis limb Hand dermatitis Rhabdomyosarcoma Angiosarcoma non-metastatic Hepatoblastoma Endometrial cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic sclerosis pulmonary

  • Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis

    Recruiting

    4 1 1
    Investigated Diseases:
    • Systemic sclerosis pulmonary
    Investigated Drugs:
    • Mycophenolate Mofetil
    • Rituximab
    France

  • Safety Study of CD19.CAR T Cells in Patients with Autoimmune‑Associated Severe Interstitial Lung Fibrosis

    Not yet recruiting

    1 1 1
    Investigated Drugs:
    • T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
    Germany

  • Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • CC-97540
    • Nintedanib
    • Fludarabine Phosphate
    Belgium France Germany Italy Spain

  • Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic sclerosis pulmonary
    Investigated Drugs:
    • Tulisokibart
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic sclerosis pulmonary
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Vixarelimab
    Belgium France Germany Greece Hungary Italy +2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!